215 Efficacy and Safety of Upadacitinib as an Induction Therapy for Patients With Moderately-to-Severely Active Ulcerative Colitis: Combined Results From 382 Subjects in the Phase 2b Study U-ACHIEVE
Peter Higgins(Michigan Medicine), Silvio Danese(IRCCS Ospedale San Raffaele), Wen Zhou(Merck & Co., Inc., Rahway, NJ, USA (United States)), Xavier Hébuterne(Université Côte d'Azur), Ana P. Lacerda(AbbVie (United States)), Jesse Siffledeen(University of Alberta), Wangang Xie(AbbVie (United States)), Fabio Cataldi(Pfizer (United States))
Cited by 1
Related Papers
Vedolizumab as Induction and Maintenance Therapy for Ulcerative Colitis
|New England Journal of Medicine|2013|2.9k
STRIDE-II: An Update on the Selecting Therapeutic Targets in Inflammatory Bowel Disease (STRIDE) Initiative of the International Organization for the Study of IBD (IOIBD): Determining Therapeutic Goals for Treat-to-Target strategies in IBD
|Gastroenterology|2021|2.6k
Selecting Therapeutic Targets in Inflammatory Bowel Disease (STRIDE): Determining Therapeutic Goals for Treat-to-Target
|The American Journal of Gastroenterology|2015|1.8k
Ustekinumab as Induction and Maintenance Therapy for Ulcerative Colitis
|New England Journal of Medicine|2019|1.2k